Efficacy of 250 mg trospectomycin sulfate i.m. vs. 250 mg ceftriaxone i.m. for treatment of uncomplicated gonorrhea. 1994

A M Rompalo, and L Colletta, and V A Caine, and P Linnemeier, and T Neumann, and E W Hook, and R B Jones
Johns Hopkins University School of Medicine, Baltimore, MD 21205.

OBJECTIVE Due to the steadily progressive development of resistance to the drugs used for treatment, Neisseria gonorrhoeae remains a medical concern. Trospectomycin sulfate is a 6' propyl analogue of spectinomycin with potent activity against penicillin sensitive and resistant strains of N. gonorrhoeae. OBJECTIVE To compare the efficacy of 250 mg trospectomycin sulfate i.m. versus 250 mg ceftriaxone i.m. for single dose therapy for men and women with uncomplicated gonorrhea. METHODS Dual-center, randomized comparative trial. RESULTS Among evaluable male patients with urethral gonorrhea, 36 of 40 (90%, 95% confidence interval [95%CI] 76%-97%) who were treated with trospectomycin sulfate were cured, and 22 of 22 patients (100%, [85%-100%]) treated with ceftriaxone were cured. Among evaluable female patients with cervical gonorrhea all were cured following trospectomycin sulfate (23 of 23) and following ceftriaxone therapy (13 of 13). The cure rates for pharyngeal gonorrhea were 67% (8 of 12 patients, 35%-90%) for trospectomycin sulfate therapy, and 100% (2 of 2) with ceftriaxone therapy. CONCLUSIONS Trospectomycin sulfate, 250 mg i.m., is effective, and well tolerated. However, for treatment of uncomplicated genital and pharyngeal gonorrhea, it is not as reliable for therapy as other recommended regimens.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010608 Pharyngeal Diseases Pathological processes involving the PHARYNX. Diseases of Pharynx,Pharynx Diseases,Disease, Pharyngeal,Disease, Pharynx,Diseases, Pharyngeal,Diseases, Pharynx,Pharyngeal Disease,Pharynx Disease
D002443 Ceftriaxone A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears. Benaxona,Cefatriaxone,Cefaxona,Ceftrex,Ceftriaxon,Ceftriaxon Curamed,Ceftriaxon Hexal,Ceftriaxona Andreu,Ceftriaxona LDP Torlan,Ceftriaxone Irex,Ceftriaxone Sodium,Ceftriaxone Sodium, Anhydrous,Ceftriaxone, Disodium Salt,Ceftriaxone, Disodium Salt, Hemiheptahydrate,Lendacin,Longacef,Longaceph,Ro 13-9904,Ro-13-9904,Ro13-9904,Rocefalin,Rocefin,Rocephin,Rocephine,Tacex,Terbac,Anhydrous Ceftriaxone Sodium,Ro 13 9904,Ro 139904,Ro13 9904,Ro139904
D002577 Uterine Cervical Diseases Pathological processes of the UTERINE CERVIX. Cervix Diseases,Cervical Disease, Uterine,Cervical Diseases, Uterine,Cervix Disease,Disease, Cervix,Disease, Uterine Cervical,Diseases, Cervix,Diseases, Uterine Cervical,Uterine Cervical Disease
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006069 Gonorrhea Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879. Neisseria gonorrhoeae Infection

Related Publications

A M Rompalo, and L Colletta, and V A Caine, and P Linnemeier, and T Neumann, and E W Hook, and R B Jones
January 1993, Drugs under experimental and clinical research,
A M Rompalo, and L Colletta, and V A Caine, and P Linnemeier, and T Neumann, and E W Hook, and R B Jones
January 1986, Sexually transmitted diseases,
A M Rompalo, and L Colletta, and V A Caine, and P Linnemeier, and T Neumann, and E W Hook, and R B Jones
January 1996, Sexually transmitted diseases,
A M Rompalo, and L Colletta, and V A Caine, and P Linnemeier, and T Neumann, and E W Hook, and R B Jones
January 1994, Sexually transmitted diseases,
A M Rompalo, and L Colletta, and V A Caine, and P Linnemeier, and T Neumann, and E W Hook, and R B Jones
January 1989, Sexually transmitted diseases,
A M Rompalo, and L Colletta, and V A Caine, and P Linnemeier, and T Neumann, and E W Hook, and R B Jones
January 1993, Sexually transmitted diseases,
A M Rompalo, and L Colletta, and V A Caine, and P Linnemeier, and T Neumann, and E W Hook, and R B Jones
August 1990, The Journal of family practice,
A M Rompalo, and L Colletta, and V A Caine, and P Linnemeier, and T Neumann, and E W Hook, and R B Jones
April 1994, Southern medical journal,
A M Rompalo, and L Colletta, and V A Caine, and P Linnemeier, and T Neumann, and E W Hook, and R B Jones
January 1987, Sexually transmitted diseases,
A M Rompalo, and L Colletta, and V A Caine, and P Linnemeier, and T Neumann, and E W Hook, and R B Jones
January 1993, Sexually transmitted diseases,
Copied contents to your clipboard!